Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Share:

 
 

Vijay K. Gunuganti, M.D.

Vijay K. Gunuganti, M.D.

Provider Type: Physician

Specialties:
  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Hematology
  • Palliative Care and Hospice

General Summary

Dr. Vijay K. Gunuganti served as a faculty member at University of Wisconsin School of Medicine and Public Health, medical oncology division, specializing in genitourinary (GU) cancers for 2 years before moving to San Antonio, Texas. He is an adjunct faculty member at UT Health San Antonio in the medical oncology division.

Education

  • Medical Doctorate
    Deccan College of Medical Sciences, Hyderabad, India
  • Internship Surgical Oncology
    Surgical-Episcopal Hospital, Temple University, Philadelphia, PA
  • Internship Internal Medicine - Chief Resident
    Medical-Marshfield Clinic, University of Wisconsin, Marshfield, WI
  • Fellowship Medical Oncology
    University of Wisconsin, Madison, WI
  • Residency
    Internal Medicine-Marshfield Clinic, University of Wisconsin, Marshfield, WI

Research Interest

Dr. Vijay K. Gunuganti is a principal investigator for several studies through US Oncology research (USOR) network. He and his site have accrued many patients in clinical trials which led to approval of many new medications in oncology. He has published many articles on Immunotherapy in cancer treatments at major national and international cancer meetings.

Other Information

Dr. Vijay K. Gunuganti is a national speaker and consultant for several pharmaceutical companies for newly approved oncology drugs. He has been educating physicians and health care providers regarding safety and efficacy healthcare on new drugs for cancers. He has been a presenter for the American Cancer Society, has presented GU updates at several Best of ASCO annual meetings and was a keynote speaker for the Women’s Health Fair in Wisconsin.

Publications

  • Safety of Nivolumab in Patients With Clear Cell (CC) or Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC): Results From the Phase IIIb/IV CheckMate 374 Study

    ASCO-GU 2019, 2019

  • Nivolumab Versus Standard of Care as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting

    World Conference on Lung Cancer, 2017

  • A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC

    Journal of Thoracic Oncology, 2016

Accolades & Memberships

  • American Society of Clinical Oncology
  • Texas Medical Association